US equities
|
MU
$1,069.73
▲+2.31%
NVDA
$236.76
▼-1.03%
SNDK
$1,708.15
▲+2.87%
AMD
$643.03
▼-0.98%
INTC
$113.48
▲+0.87%
SPCX
$168.44
▼-2.02%
TSLA
$375.41
▼-1.38%
AAPL
$335.37
▲+0.52%
MU
$1,069.73
▲+2.31%
NVDA
$236.76
▼-1.03%
SNDK
$1,708.15
▲+2.87%
AMD
$643.03
▼-0.98%
INTC
$113.48
▲+0.87%
SPCX
$168.44
▼-2.02%
TSLA
$375.41
▼-1.38%
AAPL
$335.37
▲+0.52%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
NLS Pharmaceutics Ltd. - Warrant
(NQ:
NLSPW
)
0.0179
UNCHANGED
Last Price
Updated: 3:17 PM EDT, Oct 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NLS Pharmaceutics Ltd. - Warrant
< Previous
1
2
3
4
Next >
NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term Notes
October 03, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Positive Top-Line Results from its Phase 2a Clinical Trial of Once-Daily Quilience(R) (Mazindol ER) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
September 27, 2022
Via
ACCESSWIRE
NLS Pharmaceutics To Host Virtual Key Opinion Leader Event on September 30, 2022 After Release of Quilience(R) Top-Line Phase 2a Narcolepsy Results
September 19, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development
September 08, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
July 28, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / July 28, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP), (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
July 28, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
July 21, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
July 21, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / July 21, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification
June 10, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer
June 06, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Bankruptcy
Initial Public Offering
NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy
June 02, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / June 2, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy
May 04, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering
April 26, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Regulatory Compliance
NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference
April 22, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / April 22, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 13, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / April 13, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
April 01, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / April1, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives
March 31, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / March 31, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER
March 28, 2022
- Named Patient Program (NPP) enables physicians to prescribe the Company's novel Mazindol Extended-Release (ER) formulation to patients who have failed approved therapies - Product sales through the...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference
March 25, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / March 25, 2022 - NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy
March 16, 2022
- Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline (-4.3 points placebo-adjusted); confirms statistical powering of the ongoing Phase 2a trial - Safety and...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics to Participate in the SACHS 15th Annual European Life Sciences Virtual CEO Forum and a Fireside Chat with Maxim Analyst in March
February 25, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / February 25, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics to Participate in 2022 BIO CEO & Investor Conference
February 11, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / February 11, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics to Present Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022
February 07, 2022
- Phase 2a trial meets enrollment target for interim analysis and is now more than 50% enrolled - 21 clinical sites in the United States actively enrolling patients - Nearly 90% of patients completing...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Invites Patients, Caregivers and Other Interested Parties to Attend International Narcolepsy Webinar
January 12, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation
January 04, 2022
- Key patent now granted in major markets including the U.S., Europe, Canada & South Korea - Patent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
NLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circadian Rhythm Dysregulation and Chronic Fatigue Syndrome in Long-Covid Model
November 30, 2021
STANS, SWITZERLAND / ACCESSWIRE / November 30, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
NLS Pharmaceutics CEO Issues Letter to Shareholders
November 01, 2021
STANS, SWITZERLAND / ACCESSWIRE / November 1, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Initial Public Offering
Intellectual Property
Regulatory Compliance
NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID
October 14, 2021
STANS, SWITZERLAND / ACCESSWIRE / October 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Product Recall
Regulatory Compliance
NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side
September 30, 2021
STANS, SWITZERLAND / ACCESSWIRE / September 30, 2021 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and...
From
NLS Pharmaceutics AG
Via
AccessWire
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment
September 28, 2021
STANS, SWITZERLAND / ACCESSWIRE / September 28, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
< Previous
1
2
3
4
Next >
